Transdermal iontophoresis delivery system for terazosin hydrochloride: an in vitro and in vivo study

Abstract

This study aimed to construct a transdermal iontophoresis delivery system for terazosin hydrochloride (IDDS-TEH), which included a positive and negative electrode hydrogel prescription. Intact guinea pig skin was used as a model for the skin barrier function, and the current intensity, terazosin hydrochloride (TEH) concentration, pH, competitive salt, and transdermal enhancer properties were studied. The blood drug concentration was determined in Sprague–Dawley (SD) rats using HPLC, and the antihypertensive effects of IDDS-TEH were evaluated in spontaneously hypertensive rats (SHRs). The results showed that the steady-state penetration rate of TEH increased (from 80.36 µg·cm−2·h−1 to 304.93 µg·cm−2·h−1), followed by an increase in the current intensity (from 0.10 mA·cm−2 to 0.49 mA·cm−2). The pH values also had a significant influence on percutaneous penetration. The blood concentration of IDDS-TEH was significantly higher (p < .05) than with passive diffusion, which could not be detected. The main pharmacokinetic parameters of the high current group (0.17 mA·cm−2) and the low current group (0.09 mA·cm−2) were AUC0–t: 5873.0 ng·mL−1·h and 2493.7 ng·mL−1·h, respectively. Meanwhile, the pharmacodynamic results showed that IDDS-TEH significantly decreased the blood pressure of SHRs compared with the TEH hydrogel without loading current. Therefore, TEH could be successfully delivered by the transdermal iontophoresis system in vitro and in vivo, and further clinical studies should be explored to develop a therapeutically useful protocol.

Keywords

• terazosin hydrochloride
• iontophoresis
• transdermal drug delivery
• pharmacokinetics
• blood pressure